KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Gross Margin: 2017-2025

Historic Gross Margin for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to 64.82%.

  • Aquestive Therapeutics' Gross Margin fell 242.00% to 64.82% in Q3 2025 from the same period last year, while for Sep 2025 it was 231.04%, marking a year-over-year increase of 16301.00%. This contributed to the annual value of -1,673.02% for FY2024, which is 173183.00% down from last year.
  • Aquestive Therapeutics' Gross Margin amounted to 64.82% in Q3 2025, which was up 19.14% from 54.40% recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Gross Margin high stood at 110.12% for Q4 2024, and its period low was -123.30% during Q2 2021.
  • In the last 3 years, Aquestive Therapeutics' Gross Margin had a median value of 63.10% in 2023 and averaged 65.89%.
  • Its Gross Margin has fluctuated over the past 5 years, first surged by 48,450bps in 2021, then slumped by 2,308bps in 2025.
  • Aquestive Therapeutics' Gross Margin (Quarterly) stood at 69.62% in 2021, then tumbled by 1,928bps to 50.34% in 2022, then spiked by 815bps to 58.49% in 2023, then spiked by 5,163bps to 110.12% in 2024, then slumped by 242bps to 64.82% in 2025.
  • Its last three reported values are 64.82% in Q3 2025, 54.40% for Q2 2025, and 58.12% during Q1 2025.